Director / PDMR shareholding
Director / PDMR shareholding
November 8, 2018
Download full announcement
Renalytix AI plc (AIM: RENX), a developer of artificial intelligence (“AI”) enabled clinical diagnostic solutions for kidney disease, announces that it was yesterday notified that on 6 November 2018 the following PDMR undertook a transaction in the ordinary shares of 0.25 pence each in the capital of the Company (“Ordinary Shares”), at a price of 120 pence per Ordinary Share:
| Number of Ordinary Shares bought | Resultant Interest in Ordinary Shares | Resultant Interest in Ordinary Shares (%) | |
| James McCullough Chief Executive Officer |
16,150 | 2,870,110 | 5.33 |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | James R. McCullough | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Chief Executive Officer | |||
| b) | Initial notification /Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Renalytix AI plc | |||
| b) | LEI | 213800NTOH3FK3WER551 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Ordinary shares of 0.25 pence each | |||
| Identification code | GB00BYWL4Y04 | ||||
| b) | Nature of the transaction | Purchase of Ordinary Shares | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| 120 pence | 16,150 | ||||
| d) | Aggregated information | n/a | |||
| – Aggregated volume | |||||
| – Price | |||||
| e) | Date of the transaction | 06 November 2018 | |||
| f) | Place of the transaction | London Stock Exchange | |||
Enquiries
| Renalytix AI plc
James McCullogh, CEO |
www.renalytixai.com Tel: 00 44 29 2071 0570Via Walbrook PR or Tel: +1 646 397 3970 |
| N+1 Singer (Nominated Adviser & Broker)
Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance) |
Tel: 020 7496 3000 |
| Walbrook PR Limited Paul McManus Lianne Cawthorne |
Tel: 020 7933 8780 or ekf@walbrookpr.com Mob: 07980 541 893 / 07584 391 303 |